Brief: Foghorn Therapeutics Presents New Preclinical Data On Potential First-In-Class BRM Selective Inhibitor FHD-909 And Selective CBP And Selective EP300 Degrader Oncology Programs
09/04/2024 22:23
April 9 (Reuters) - Foghorn Therapeutics Inc. FHTX.O :
* FOGHORN THERAPEUTICS PRESENTS NEW PRECLINICAL DATA ON
POTENTIAL
FIRST-IN-CLASS BRM SELECTIVE INHIBITOR FHD-909 AND SELECTIVE CBP
AND SELECTIVE EP300 DEGRADER ONCOLOGY PROGRAMS
* FOGHORN THERAPEUTICS INC. - ROBUST PRECLINICAL MONOTHERAPY
ANTI-TUMOR ACTIVITY FOR BOTH SELECTIVE CBP AND SELECTIVE EP300
DEGRADER PROGRAMS
* FOGHORN THERAPEUTICS INC. - FHD-909 DEMONSTRATED FAVORABLE
TOLERABILITY AND DOSE-DEPENDENT SINGLE AGENT ACTIVITY IN BRG1
MUTATED CANCERS PRECLINICALLY
Source text for Eikon: ID:nGNX1n3pBq
Further company coverage: FHTX.O
((Reuters.Briefs@thomsonreuters.com;))